San Diego, California – ADARx Pharmaceuticals disclosed on Monday that it is pursuing a U.S. initial public offering (IPO) that could value the biotech firm at as much as $1.74 billion. The company aims to raise up to $371.9 million by selling 21.9 million shares priced between $15 and $17 each.
Offering details and underwriters
The IPO will be listed on the Nasdaq under the ticker symbol “ADRX.” Leading investment banks JP Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank and LifeSci Capital have been named as underwriters for the transaction.
Strategic partnership with AbbVie
In a concurrent private placement, pharmaceutical giant AbbVie has agreed to purchase shares that will give it an approximate 4.9% ownership stake in ADARx after the public offering closes. The partnership is expected to provide ADARx with additional capital and strategic support as it advances its pipeline of oncology and immunology therapies.
Market context
Biotech IPO activity has been buoyed by strong investor appetite for innovative drug developers, even as rising Treasury yields and higher interest rates have created a more challenging environment for new listings. Higher borrowing costs can compress valuation multiples, prompting some companies to delay offerings until market conditions stabilize.
Despite these headwinds, ADARx’s management remains confident that the company’s robust clinical data and expanding pipeline will attract sufficient demand from institutional and retail investors.
Company background
Founded in 2018, ADARx focuses on developing targeted therapies for rare cancers and immune‑mediated diseases. The firm’s lead candidate, ADX‑101, is in Phase II trials for a rare form of lymphoma, while several other programs are advancing through pre‑clinical and early‑stage clinical testing.
CEO Dr. Maya Patel said, “Our IPO will provide the resources needed to accelerate development of life‑saving treatments and bring them to patients faster. Partnering with AbbVie further validates our scientific approach and positions us for long‑term growth.”
Investor outlook
Analysts note that the biotech sector’s recent performance has been mixed, but companies with differentiated pipelines and strong cash positions tend to outperform. The involvement of a major pharmaceutical partner like AbbVie is viewed as a positive signal for ADARx’s future prospects.
Potential investors are advised to consider the company’s clinical milestones, the competitive landscape for its target indications, and the broader macro‑economic environment when evaluating the offering.
Next steps
The company expects to price the shares and begin trading on Nasdaq in the coming weeks, subject to market conditions and regulatory approvals. Interested parties can find additional information in the company’s filing with the U.S. Securities and Exchange Commission.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
